Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones.
December 13, 2022 | LifeSciVC
Takeda Acquires Nimbus’ Tyk2 Autoimmune Program
July 27, 2022 | From the Trenches
You Can’t Do It Alone – The Importance of Riding the Same Bus
From academic research, patent law, business development, to being a CEO, all my experiences have taught me two things. First, one cannot do it all alone (especially in biotech). Second, the biotech ecosystem is unique in a sense that everyone, irrespective of background, shares the same goal: to improve patient lives.
By Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC
July 6, 2022 | LifeSciVC
Surprising Resilience Of Private VC-Backed Biotech Markets
It’s biotech armageddon out there: with massive value destruction across public stocks, it’s clearly the worst market backdrop in over 20 years.
June 29, 2022 | Uncategorized
Atlas Venture’s Recent Leadership & Team Additions
Biotech venture creation is a team endeavor. We work with the best teams in the business. Meet some of our new CEOs and the most recent additions to our investment team in our newsletter.
June 28, 2022 | From the Trenches
This Too Shall Pass
Although I intend to shy away from the cult of celebrity, a recent clip from Tom Hanks resonated with me regarding the current state of the biotech market. As Mr Hanks continues his evolution into that trusted grandfatherly type of statesman, he spoke sagely with a group of peers and juniors reminding them all that “This too shall pass”.
By Robert Clarke, CEO of Kinaset, as part of the From The Trenches feature of LifeSciVC.